CCM
PHAT icon

CAAS Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

CAAS Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-210,973
Closed -$7.92M – 1230
2021
Q1 		$7.92M Buy
210,973
+194,126
+1,152% +$8.12M 0.09% 260
2020
Q4 		$560K Buy
+16,847
New +$683K 0.01% 681

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAAS Capital Management's PHAT Position: Q2 2021 in Review

CAAS Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2021, closing a stake of 210,973 shares — an estimated $7.92M sold.

CAAS Capital Management first reported a position in PHAT in Q4 2020 and held it in 2 quarters. The position peaked at $7.92M in Q1 2021. 79 funds tracked by Wall St. Rank hold PHAT as of Q2 2021.

  • CAAS Capital Management reported no remaining Phathom Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 210,973 Phathom Pharmaceuticals shares in Q2 2021, an estimated $7.92M.
  • CAAS Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's Phathom Pharmaceuticals position peaked at $7.92M in Q1 2021.
  • 79 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.